Arcturus Therapeutics (ARCT) Set to Announce Quarterly Earnings on Thursday

by · The Cerbat Gem

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) is set to release its earnings data after the market closes on Thursday, November 7th. Analysts expect Arcturus Therapeutics to post earnings of ($0.70) per share for the quarter.

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($1.85) by $1.21. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. The business had revenue of $49.86 million during the quarter, compared to analysts’ expectations of $21.00 million. During the same period last year, the firm posted ($1.98) EPS. On average, analysts expect Arcturus Therapeutics to post $-3 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Arcturus Therapeutics Stock Up 2.4 %

Shares of ARCT traded up $0.42 during midday trading on Friday, reaching $18.15. 12,952 shares of the stock were exchanged, compared to its average volume of 466,329. Arcturus Therapeutics has a twelve month low of $17.52 and a twelve month high of $45.00. The stock’s 50 day simple moving average is $20.94 and its 200 day simple moving average is $24.64. The company has a market cap of $488.78 million, a P/E ratio of -6.90 and a beta of 2.61.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. Leerink Partners assumed coverage on Arcturus Therapeutics in a research report on Monday, August 12th. They issued an “outperform” rating and a $70.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $71.40.

Get Our Latest Report on ARCT

Insider Transactions at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the sale, the chief operating officer now owns 435,334 shares in the company, valued at $9,037,533.84. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 15.30% of the company’s stock.

About Arcturus Therapeutics

(Get Free Report)

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

Featured Articles